Biotech Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Finance
Company raises $16M to advance stem cell-based therapies
June 6th, 2005
Cellerant Therapeutics, Inc., announced that it has raised $16 million in a series B financing led by Novel Bioventures. Participants in this round included George Rathmann and CX Venture Group. Allen & Co. and MPM Capital were among the series A stockholders who also invested in this financing. "Cellerant represents one of the strongest and most impressive platforms and management teams for commercializing stem-cell products," said Han Chiu, MD, managing director of Novel Bioventures. "The company has significant near-term revenue opportunities and is attracting a rich pipeline of ever-more exciting technologies and breakthroughs. Novel is pleased...
Source: Biotech Business Week (2005-06-06)
|
